| Guo, Ye |
MRG003-010, NCT05751512: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN |
|
|
| Not yet recruiting | 3 | 180 | RoW | MRG003, Cetuximab injection, Methotrexate Injection | Shanghai Miracogen Inc. | Squamous Cell Carcinoma of the Head and Neck | 08/25 | 12/25 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04868162: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck |
|
|
| Recruiting | 2 | 120 | RoW | MRG003 | Shanghai Miracogen Inc. | Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | 01/23 | 09/23 | | |
NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | SI-B001 | Sichuan Baili Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinoma | 06/25 | 06/25 | | |
NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | SI-B001, Paclitaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinoma | 06/25 | 06/25 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT06194656: Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 81 | RoW | HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo, Cetuximab injection | Shanghai Institute Of Biological Products | Head and Neck Squamous Cell Carcinoma | 07/26 | 07/26 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
HG146, NCT06781567: Clinical Trial of Administered to Participants with Adenoid Cystic Carcinoma |
|
|
| Recruiting | 2 | 140 | RoW | HG146, HG146 Capsule | HitGen Inc. | Adenoid Cystic Carcinoma, Head and Neck Cancer | 12/28 | 06/29 | | |
NCT06007729: ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 2 | 170 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Head and Neck Squamous Cell Carcinoma | 12/25 | 12/27 | | |
NCT04856631: A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer |
|
|
| Recruiting | 1/2 | 88 | RoW | Toripalimab Injection, Cetuximab Solution for infusion | Shanghai Junshi Bioscience Co., Ltd. | Head and Neck Squamous Cell Cancer | 11/22 | 11/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05668858: Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 40 | RoW | SI-B001, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Squamous Cell Carcinoma of Head and Neck | 06/25 | 12/25 | | |
NCT05839106: Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1032 injection, PM1032 | Biotheus Inc. | Advanced Tumor | 04/25 | 12/25 | | |
NCT05862831: Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 285 | RoW | PM1003 Injection | Biotheus Inc. | Advanced Solid Tumors | 09/25 | 11/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | YL-13027 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumors | 04/21 | 06/22 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
NCT06292858: Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 93 | RoW | IMB071703 injection | Beijng Immunoah Pharma Tech Co., Ltd. | Recurrent or Metastatic, Advanced Solid Tumors | 04/25 | 08/25 | | |
NCT05552807: SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 1 | 120 | RoW | SCT-I10A, SCT200, paclitaxel, docetaxel | Sinocelltech Ltd. | Head and Neck Squamous Carcinoma | 09/23 | 09/23 | | |
NCT06225856: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies |
|
|
| Recruiting | 1 | 96 | RoW | YY201 | Shanghai Yuyao Biotech Co., Ltd. | Advanced Solid Tumor, Hematological Malignancy | 12/26 | 12/26 | | |
NCT05607563: A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours |
|
|
| Recruiting | 1 | 54 | RoW | PM1009 injection, PM1009 | Biotheus Inc. | Advanced Tumor | 11/23 | 12/23 | | |
NCT04472858: A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Donafenib, CS1001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, CStone Pharmaceuticals | Advanced Solid Tumor | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
NCT05429008: A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm |
|
|
| Recruiting | 1 | 99 | RoW | HMPL-A83 injection, HMPL-A83 | Hutchmed | Advanced Tumors | 06/25 | 09/25 | | |
NCT06304571: A Study of HC006 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 76 | RoW | HC006 | HC Biopharma Inc. | Advanced Solid Tumor | 03/26 | 07/26 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
NCT04659369: Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC |
|
|
| Terminated | 1 | 21 | RoW | CMAB819, Nivolumab, Opdivo | Taizhou Mabtech Pharmaceutical Co.,Ltd | Squamous Cell Carcinoma of the Head and Neck | 10/23 | 10/23 | | |
NCT06469008: A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Head and Neck Squamous Cell Carcinomas, Solid Tumor | 07/26 | 07/26 | | |
NCT05490043: A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 62 | RoW | ATG-101 | Antengene (Hangzhou) Biologics Co., Ltd. | Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma | 08/24 | 12/24 | | |
| Recruiting | 1 | 144 | US, RoW | ADRX-0706 | Adcentrx Therapeutics | Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer | 09/25 | 12/26 | | |
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 141 | Europe, Canada, Japan, US, RoW | GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227 | GlaxoSmithKline | Neoplasms | 09/28 | 09/28 | | |
| Wang, Peiguo |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT04782765: Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 59 | RoW | Camrelizumab+Chemotherapy+Chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital | Disease-free Survival Rate | 03/23 | 03/25 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
Redbull-1, NCT04949503: A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN |
|
|
| Completed | N/A | 1931 | RoW | nimotuzumab, chemoradiotherapy | Biotech Pharmaceutical Co., Ltd. | Locally Advanced Head and Neck Squamous Cell Carcinoma | 03/23 | 04/23 | | |
| McCollum, Michael E |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
|
|
| Completed | 2 | 79 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IMGN853 | AbbVie | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 01/24 | 12/24 | | |
|
|
|
|
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
|
|
| Active, not recruiting | 2 | 102 | Europe, US, RoW | ZN-c3, azenosertib | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 04/25 | 10/25 | | |
| Tong, Zhongsheng |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
NCT05871918: A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer |
|
|
| Recruiting | 3 | 832 | RoW | TCbHP VS ddEC-THP | Tianjin Medical University Cancer Institute and Hospital | HER-2 Positive Breast Cancer | 12/23 | 12/23 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 06/25 | 12/26 | | |
NCT04907344: Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2/3 | 420 | RoW | Camrelizumab, Nab-Paclitaxel, Carboplatin | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Triple Negative Breast Cancer | 06/25 | 06/25 | | |
NCT04733417: A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. |
|
|
| Active, not recruiting | 2 | 35 | RoW | SHR6390, famitinib | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Advanced Breast Cancer, Metastatic Breast Cancer | 08/22 | 09/23 | | |
NCT04988165: Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine |
|
|
| Recruiting | 2 | 30 | RoW | Traditional Chinese Medicine | Tianjin Medical University Cancer Institute and Hospital | Diarrhea Caused by Antitumor Drugs | 10/22 | 10/22 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT05560334: A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations |
|
|
| Recruiting | 2 | 20 | RoW | Pemigatinib Pill, Pemazyre | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 09/24 | 09/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 60 | RoW | PM8002, nab-paclitaxel | Biotheus Inc. | TNBC | 10/26 | 10/26 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT04526028: Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China |
|
|
| Recruiting | N/A | 612 | RoW | Fulvestrant Injectable Product, Palbociclib | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer, Fulvestrant, Palbociclib | 02/23 | 05/23 | | |
| LU, Jin |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
| Recruiting | 2 | 21 | RoW | SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone | Peking University People's Hospital, Qingdao Municipal Hospital | Multiple Myeloma | 07/24 | 07/25 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT06727721: Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus |
|
|
| Recruiting | 2 | 10 | RoW | mesenchymal stem cells with OCN-19, Mesenchymal stem cells, albumin injection | Lu jin ，MD | Diabetes, Type 2 Diabetes | 12/28 | 12/29 | | |
NCT06342466: Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis |
|
|
| Recruiting | 2 | 40 | RoW | Bortezomib, Velcade, Pomalidomide, Dexamethasone | Jin Lu, MD | Systemic Amyloidosis | 12/26 | 12/26 | | |
NCT06418477: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD |
|
|
| Recruiting | 2 | 20 | RoW | Dara-CyBorD | Peking University People's Hospital | Monoclonal Gammopathy of Renal Significance | 12/25 | 12/26 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT06049290: A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 418 | RoW | LBL-034 for Injection, LBL-034 | Nanjing Leads Biolabs Co.,Ltd | Relapsed/Refractory Multiple Myeloma | 10/26 | 05/27 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT05438394: Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM |
|
|
| Recruiting | 1 | 24 | RoW | melphalan hydrochloride for injection | Peking University People's Hospital, CASI Pharmaceuticals, Inc. | Multiple Myeloma | 12/23 | 12/23 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT06655519: An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
|
|
| Not yet recruiting | 1 | 12 | NA | CAR-T（RD140 injection） | Peking University People's Hospital | Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | 07/28 | 07/41 | | |
NCT01250808: Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy |
|
|
| Available | N/A | | RoW | Bortezomib/Dexamethasone/Melphalan | Peking University | Multiple Myeloma | | | | |
NCT06192979: Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
|
|
| Recruiting | N/A | 41 | RoW | Daratumumab, Bortezomib, Dexamethasone, Venetoclax | Jin Lu, MD | Amyloidosis; Systemic, AL Amyloidosis | 12/25 | 06/26 | | |
NCT06369935: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. |
|
|
| Not yet recruiting | N/A | 260 | RoW | Equecabtagene Autoleucel, CT103A | Peking University People's Hospital | Relapsed/Refractory Multiple Myeloma | 08/26 | 08/27 | | |
NCT06699394: Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis |
|
|
| Recruiting | N/A | 20 | RoW | Teclistamab (Tec) | Peking University People's Hospital | AL Amyloidosis | 12/25 | 12/26 | | |
| Recruiting | N/A | 175 | RoW | | Peking University People's Hospital, Peking University Cancer Hospital & Institute | Diffuse Large B Cell Lymphoma | 04/25 | 04/27 | | |
| Chen, Jie |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma |
|
|
| Recruiting | 4 | 360 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Medullary Thyroid Cancer | 06/27 | 12/28 | | |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease (CD) | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 121 | Europe, Canada, Japan, US, RoW | Vedolizumab, MLN0002, ENTYVIO, KYNTELES | Takeda, Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 08/25 | 08/25 | | |
| Recruiting | 3 | 240 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention | Takeda, Takeda Development Center Americas, Inc. | Ulcerative Colitis, Crohn's Disease | 08/31 | 08/31 | | |
